DSCO

AcronymDefinition
DSCODiscovery Laboratories, Inc. (Warrington, PA)
DSCODeputy State Coordinating Officer (various organizations)
DSCODistrict Soil Conservation Office (Nepal)
DSCODemocratic Socialists of Central Ohio (Columbus, OH)
DSCODirector of State Courts Office (Wisconsin)
DSCODirector Supply Chain Operations
DSCODeep Space Climate Observatory
DSCODental Study Club Online (online journal)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
HE Dr Aisha Bint Butti Bin Bishr, Director General of DSCO,
all DSG sectors and the harmony of DSG strategy with DSCO. This consists of
(RAE608) ROBERT CAPETOLA - DISCOVERY LABORATORIES INC (DSCO).
(Nasdaq: DSCO), Doylestown, Pa., a biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases, has initiated a Phase 1b clinical trial to evaluate the safety and tolerability of its humanized lung surfactant, delivered as an inhaled aerosol, to treat hospitalized patients who suffer from asthma.
15 October 2010 - US Discovery Laboratories Inc (NASDAQ: DSCO) said today that W.
15 October 2010 - US Discovery Laboratories Inc (NASDAQ: DSCO) said today that the Phase IIa study of aerosolised KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has been completed.
13 October 2010 - US biotechnology company Discovery Laboratories Inc (NASDAQ: DSCO) said today it has signed an agreement for a new investment of USD500,000 (EUR358,000) from PharmaBio Development Inc, the former strategic investing subsidiary of Quintiles Transnational Corp.
24 February 2010 - US biotechnology company Discovery Laboratories Inc (NASDAQ: DSCO) said on 16 February that, in response to a written guidance received from the US Food and Drug Administration (FDA), it will now focus on a pathway that would entail solely performing additional preclinical work, instead of conducting a limited clinical trial, to potentially gain FDA marketing approval for Surfaxin (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
OWe are proud to receive this recognition from Supply & Demand Chain Executive,O stated David Kahlow, DSCOs director of sustainability.